A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Chao XuPatanjali RavvaJun Steve DangJohann LaurentCéline AdessiChristine McIntyreGeorgina Meneses-LorenteFrancois MercierPublished in: Cancer chemotherapy and pharmacology (2018)
This work shows that PK-toxicity modeling provides insight into how the severity of key adverse events evolves over time and highlights the potential use to support decision making in drug development.